Chen, Xudong
Xie, Min
Zhang, Sensen
Monguió-Tortajada, Marta http://orcid.org/0000-0003-2125-0810
Yin, Jian
Liu, Chang
Zhang, Youqi
Delacrétaz, Maeva http://orcid.org/0009-0003-4154-5277
Song, Mingyue
Wang, Yixue http://orcid.org/0000-0001-5254-5940
Dong, Lin
Ding, Qiang http://orcid.org/0000-0002-6226-869X
Zhou, Boda
Tian, Xiaolin
Deng, Haiteng
Xu, Lina
Liu, Xiaohui
Yang, Zi
Chang, Qing http://orcid.org/0000-0002-9259-7734
Na, Jie http://orcid.org/0000-0003-1820-0548
Zeng, Wenwen http://orcid.org/0000-0001-8544-3318
Superti-Furga, Giulio http://orcid.org/0000-0002-0570-1768
Rebsamen, Manuele http://orcid.org/0000-0001-6172-4211
Yang, Maojun http://orcid.org/0000-0002-6798-3094
Article History
Received: 24 March 2023
Accepted: 4 October 2023
First Online: 20 October 2023
Competing interests
: CeMM and the Medical University of Vienna are the applicants of European priority patent applications (EP 22 203 423.3, EP 22 203 422.5, EP 22 203 421.7, status: filed) in which M.R. and G.S.-F are listed as inventors, covering small-molecule modulators of TASL and their medical use. G.S.-F. is founder and shareholder of Solgate, a company focused on SLC inhibitors. The other authors declare no competing interests.